FilingReader Intelligence
Jiudian Pharmaceutical gets green light for PDX-04 clinical trials
May 26, 2025 at 05:24 PM UTC•By FilingReader AI
Hunan Jiudian Pharmaceutical (SZSE:300705) announced that it has received approval from the National Medical Products Administration to conduct clinical trials for PDX-04, a chemical drug categorized as Class 2.2. The drug is intended for pain relief in acute gout attacks. The company submitted applications CXHL2500288 and CXHL2500289 in March 2025, and the approval allows Jiudian Pharmaceutical to proceed with clinical trials.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SZSE:300705•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Hunan Jiudian Pharmaceutical publishes news
Free account required • Unsubscribe anytime